EUVIMEDOpdag EUVIMED
Klinische Studie (Phase II)Randomisierte kontrollierte StudieKlinische Studie (Phase I)

Effects of a pro‐resolving drug in COVID‐19: preclinical studies to a randomized, placebo‐controlled, phase Ib/IIa trial in hospitalized patients

Pedro R J Almeida, Alexandre M Periard, Fernanda L Tana, Renata E Avila, Larissa B Milhorato, Katlen M M Alcantara, Carolina B Resende, Angela V Serufo, Felipe R Santos iD, Danielle C Teixeira, Celso M Queiroz-Junior, Talita C M Fonseca and 6 more

British Journal of Pharmacology · 2024

DOI: 10.1111/bph.17322 ↗

At a glance

Klinische Studie (Phase II) in British Journal of Pharmacology, 2024. Written by Pedro R J Almeida and 17 co-authors. Institution: Center for Advanced and Innovative Therapies, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. Major MEDLINE topics: Mice, Inbred C57BL, COVID-19 Drug Treatment, COVID-19, SARS-CoV-2. Cited 8 times so far (Crossref); 42 references. Funded by: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), Conselho Nacional de Desenvolvimento Científico e Tecnologico (CNPq).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Pro‐resolving molecules may curb disease caused by viruses without altering the capacity of the host to deal with infection. AP1189 is a melanocortin receptor‐biased agonist endowed with pro‐resolving and anti‐inflammatory activity. We evaluated the preclinical and early clinical effects of treatment with AP1189 in the context of COVID‐19.

Methods

C57BL/6j mice were infected intranasally with MHV‐A59 or hK18‐ACE2 mice with SARS‐CoV‐2. AP1189 (10 mg·kg −1 , BID, s.c.) was given to the animals from day 2 and parameters evaluated at day 5. Human PBMCs from health donors were infected with SARS‐CoV‐2 in presence or absence of AP1189 and production of cytokines quantified. In the clinical study, 6 patients were initially given AP1189 (100 mg daily for 14 days) and this was followed by a randomized (2:1), placebo‐controlled, double‐blind trial that enrolled 54 hospitalized COVID‐19 patients needing oxygen support. The primary outcome was the time in days until respiratory recovery, defined as a SpO 2 ≥ 93% in ambient air.

Results

Treatment with AP1189 attenuated pulmonary inflammation in mice infected with MHV‐A59 or SARS‐CoV‐2 and decreased the release of CXCL10, TNF‐α and IL‐1β by human PBMCs. Hospitalized COVID‐19 patients already taking glucocorticoids took a median time of 6 days until respiratory recovery when given placebo versus 4 days when taking AP1189 ( P = 0.017).

Conclusion

Treatment with AP1189 was associated with less disease caused by beta‐coronavirus infection both in mice and in humans. This is the first demonstration of the effects of a pro‐resolving molecule in the context of severe infection in humans.

Subjects

MeSH terms (MEDLINE)

Mice, Inbred C57BLCOVID-19 Drug TreatmentCOVID-19SARS-CoV-2HumansAnimalsMaleMiddle AgedFemaleMiceDouble-Blind MethodAgedAdultCytokinesHospitalizationLeukocytes, Mononuclear

Author keywords

COVID‐19melanocortinresolution of inflammationresolution pharmacology

Substances

Cytokines

Authors and institutions

  • Center for Advanced and Innovative Therapies, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
  • Hospital Eduardo de Menezes, Belo Horizonte, Brazil.
  • Genetics Department, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
  • William Harvey Research Institute, Queen Mary University of London, London, UK.
  • Synact Pharma Aps, Holte, Denmark and Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Biochemistry and Immunology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

ORCID profiles: Felipe R Santos, Renan P Souza, Mauro Perretti, Mauro M Teixeira

Funding

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG)
  • Conselho Nacional de Desenvolvimento Científico e Tecnologico (CNPq)

Cite

APA

Almeida, P. R. J., Periard, A. M., Tana, F. L., Avila, R. E., Milhorato, L. B., Alcantara, K. M. M., Resende, C. B., Serufo, A. V., Santos, F. R., Teixeira, D. C., Queiroz-Junior, C. M., Fonseca, T. C. M., Silva, B. L. V., Costa, V. V., Souza, R. P., Perretti, M., Jonassen, T. E. N., & Teixeira, M. M. (2024). Effects of a pro‐resolving drug in COVID‐19: preclinical studies to a randomized, placebo‐controlled, phase Ib/IIa trial in hospitalized patients. British Journal of Pharmacology. https://doi.org/10.1111/bph.17322

Vancouver

Almeida PRJ, Periard AM, Tana FL, Avila RE, Milhorato LB, Alcantara KMM, et al. Effects of a pro‐resolving drug in COVID‐19: preclinical studies to a randomized, placebo‐controlled, phase Ib/IIa trial in hospitalized patients. British Journal of Pharmacology. 2024. doi:10.1111/bph.17322

BibTeX
@article{Almeida2024,
  author = {Almeida, Pedro R J and Periard, Alexandre M and Tana, Fernanda L and Avila, Renata E and Milhorato, Larissa B and Alcantara, Katlen M M and Resende, Carolina B and Serufo, Angela V and Santos, Felipe R and Teixeira, Danielle C and Queiroz-Junior, Celso M and Fonseca, Talita C M and Silva, Barbara L V and Costa, Vivian V and Souza, Renan P and Perretti, Mauro and Jonassen, Thomas E N and Teixeira, Mauro M},
  title = {Effects of a pro‐resolving drug in COVID‐19: preclinical studies to a randomized, placebo‐controlled, phase Ib/IIa trial in hospitalized patients},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.17322}
}
Start for free →